In collaboration with the Department of Neuropsychology and Psychopharmacology of the Maastricht University, we’ve launched the first scientific Microdosing for ADHD/ADD study. We have teamed up because we are both interested in the effects of self-medicating with psychedelic microdoses to relieve symptoms of ADHD (Attention Deficit Hyperactivity Disorder) or ADD (Attention Deficit Disorder).
The information below is written by the research team at Maastricht University:
Goal of the study
With this project, we want to investigate the effects of microdosing with psychedelics (e.g. LSD, psilocybin) on mood, social functioning and cognitive performance of adults with ADHD/ADD. By social functioning, we mean your ability to regulate your own emotions and how you deal with the emotions of other people. By cognitive performance, we mean in this case your ability to perceive and estimate time durations.
We also would like to know what substance, and what kind of Microdosing protocol people use for ADHD. The Microdosing Institute protocol (Every other day protocol), the Fadiman protocol or maybe a different scheme.
Our project will focus on adults that meet the DSM-5 criteria for ADHD/ADD, that experience interference in their daily functioning. ADHD/ADD is one of the most prevalent developmental disorders worldwide, characterized by deficits in attention, psychomotor agitation and/or impulsivity that are not age-appropriate.
We are first and most interested in individuals that are not using standard medication like Ritalin for ADHD/ADD, but intend to microdose with psychedelics on their own initiative. We take into account that there will be individuals that will be using both (standard medication and psychedelic microdoses), or that there will be individuals who are not diagnosed with ADHD/ADD but experience symptoms that interfere with their daily life and therefore want to self-medicate with microdoses of psychedelics. We will ask about your experience with psychedelic substances in full- and microdoses to estimate how experienced you are with the effects of these compounds.
It has been thought previously that patients outgrow this disorder. Now, we know that about 65% of patients experience ADHD/ADD symptoms also throughout adulthood, of which 1 out of 7 individuals experience difficulties controlling his/her behavior and emotions. These symptoms lead to disturbances in daily functioning of the patient and his/her environment. As described earlier, conventional treatments do not seem to effectively treat the symptoms in a great number of cases. Also, these conventional treatments seem insufficient in dealing with emotional difficulties patients may experience.
When you decide to participate in our study, you should know that you have all rights to stop participating at any moment without giving any reason why, without any consequences.
Procedure of participation
Because we want to test what the effects of microdosing with psychedelics are on well-being and functioning, we will be conducting measurements at baseline and two and four weeks after the start of microdosing. These measurements consist of questionnaires (baseline measurement: 15-20 minutes, following measurements: 10-15 minutes) and a cognitive task (4-5 minutes). Further, we will ask you to complete a short questionnaire (2 minutes) every day. All questionnaires will be in English, including the computer task assessing your perception of time.
Baseline and following measurements
You are supposed to complete the baseline measurement between 1 and 3 days before you will start microdosing with psychedelics for ADHD/ADD. We will use this measurement as baseline to which we will compare the following measurements. The two following measurements will take place two and four weeks after you started microdosing. In these three measurements, you will be answering questions about your personality, ADHD/ADD symptoms, mood, well-being and we will be assessing your cognitive performance. Additionally, in the first measurement we will ask about your history of drug use.
By cognitive performance we mean in this case how well you perform on a task that measures your perception of time. Each of the three measurements will take up to 20 minutes of your time.
If the second or third measurement will take place on days you planned to take a microdose, you should complete the questionnaires and cognitive task first before taking a microdose. This is needed to compare the measurements to the baseline measurement.
Short daily questionnaire
We want to know how you are doing every day. You will complete a short questionnaire of two minutes every day, where we will be asking questions about your sleep (quality and how long) and mood. We will also ask whether you took a microdose and/or medication that day. On the first day you will take a microdose we want you to complete the computer task again to test acute effects of microdosing on your perception of time. Based on when you took the microdose, you will be asked to complete the computer task again when completing the short questionnaire.
We will be asking some personal data that will be saved on a secured server at Maastricht University. Only researchers involved in this study will have access to this data. Data that will be securely saved:
ADHD/ADD diagnosis (questionnaire)
Drug use (questionnaire)
During the sign up process, we will also ask for your email address. This will only be used to send you the measurements at the right moments. The email address will be automatically deleted once your participation has ended.
To protect your privacy, this data will be anonymized, meaning that it is not in any way traceable to you.
Risks and possible discomforts
There are no risks connected to your participation in this research. We do not promote or stimulate the use of psychedelics. The University cannot be held responsible for any possible negative effects or discomforts experienced after using psychedelics on own initiative.
Because there has not been much research done into the possible harmful effects of psychedelics, we cannot exclude the possibility that using these substances may have negative effects on the short or long term.
There are no direct benefits connected to your participation in this research. Although, you are contributing to the knowledge we need to explain controlled lab research to for example a grant provider.
You can withdraw your consent to use your personal data at any moment. In that case will all personal and research data be deleted. For more information about your rights, please go to www.maastrichtuniversity.nl/fpn/ercpn and see ‘personal information and privacy’ among ‘Fast Facts’. If you have questions about the processing of your personal data or about the rights of the participants, you can contact the responsible researcher (firstname.lastname@example.org). You could also contact the data protection officer at Maastricht University: email@example.com .
Important: When to sign up?
The study is ONLY designed for participants who are about to start their microdosing journey.
Please only sign up when you have your microdoses sourced, and are ready to get started.
Are you based in Europe?
You might be eligible for getting your Microdosing products partially sponsored by Microdose.nl*
As you may know, Microdosing Institute is supported by our partner web shop Microdose.nl
As a supporter of our research goals and those who could benefit from this Microdosing ADHD/ADD study now and in the future, Microdose.nl sponsors participants with a 20% discount code on their microdoses. For instance the MicrodosingXP truffles (packed in 6×1 gram strips) or one of the other legal microdosing products.
Send an email to firstname.lastname@example.org with a screenshot of your enrollment, and you will receive your 20% discount code. (Valid until 31-06-2021)
*some countries are excluded due to shipping restrictions